Related references
Note: Only part of the references are listed.Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice
Olivier Outteryck et al.
JOURNAL OF NEUROLOGY (2010)
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
A. B. Oturai et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
N. Putzki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The pharmacovigilance program on natalizumab in Italy: 2 years of experience
G. Tedeschi et al.
NEUROLOGICAL SCIENCES (2009)
GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
A. D. Goodman et al.
NEUROLOGY (2009)
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Hans Linda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire
R. H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
Natalizumab: a country-based surveillance program
Gian Luigi Mancardi et al.
NEUROLOGICAL SCIENCES (2008)
The incidence and significance of anti-natalizumab antibodies -: Results from AFFIRM and SENTINEL
P. A. Calabresi et al.
NEUROLOGY (2007)
Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test
B. A. Parmenter et al.
MULTIPLE SCLEROSIS JOURNAL (2007)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales
JC Hobart et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Multiple sclerosis severity score -: Using disability and disease duration to rate disease severity
RHSR Roxburgh et al.
NEUROLOGY (2005)
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples
A Riazi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2002)
Share Paper
